4DMT to Present at Clinical Trials Summit 2024
EMERYVILLE, Calif., June 04, 2024 – 4D Molecular Therapeutics (Nasdaq: FDMT), a prominent clinical-stage genetic medicines company, has announced its participation in the Clinical Trials at the Summit (CTS) Meeting, scheduled for June 8, 2024, in Park City, Utah. The company's presence at this high-profile event signifies its commitment to advancing genetic medicine.
Overview of CTS 2024 Participation
At the CTS Meeting, 4DMT will present crucial updates and insights through a series of discussions and presentations. The schedule is as follows:
Panel Discussions:
1. Designing Registration Trials with the Latest FDA Guidance
- Time: 1:49-2:09 p.m. MDT
- Panelist: Dr. Robert Kim, Chief Medical Officer at 4DMT
2. Challenges of Bringing New Treatment Options to Market
- Time: 3:40-4:00 p.m. MDT
- Panelist: Dr. David Kirn, Co-founder and CEO of 4DMT
Scientific and Corporate Presentations:
1. 24-week Results from the Randomized Phase 2 Dose Expansion Stage of PRISM Trial Evaluating 4D-150 in High Need nAMD Patients
- Session: Gene Therapy and Optogenetics
- Time: 2:16-2:20 p.m. MDT
- Presenter: Dr. Carl Danzig, Rand Eye Institute, Deerfield Beach, FL
2. 4DMT Corporate Overview
- Time: 2:53-2:58 p.m. MDT
- Presenter: Dr. David Kirn, Co-founder and CEO of 4DMT
For those interested in a detailed preview of the company’s progress, the presentation on 4D-150 will be accessible on the 4DMT website.
About 4DMT
4D Molecular Therapeutics is a trailblazing company in the field of genetic medicines, concentrating on the development of therapies for significant market diseases in areas such as ophthalmology and pulmonology. The company’s proprietary platform, Therapeutic Vector Evolution, merges directed evolution—a technology that earned a Nobel Prize—with around one billion synthetic AAV capsid-derived sequences. This combination enables the creation of bespoke and evolved vectors tailored for the company’s product candidates, both owned and partnered.
4DMT’s robust product pipeline is driven by its inventive design, development, and manufacturing capabilities, aiming to revolutionize medical treatments with potentially curative therapies for millions. The company is currently advancing five clinical-stage candidates and two preclinical candidates. These are designed to address both rare and widespread conditions in ophthalmology, pulmonology, and cardiology. Moreover, 4DMT is progressing in the field of central nervous system (CNS) disorders through a gene editing partnership.
Despite the promising advancements, it is important to note that all of 4DMT’s product candidates are still in clinical or preclinical stages and have not received approval from the U.S. Food and Drug Administration (FDA) or any other regulatory bodies. Therefore, no claims can be made about the safety or effectiveness of these treatments as they are still under investigation.
By participating in the CTS Meeting, 4DMT showcases its commitment to pioneering genetic medicine and addressing unmet medical needs through innovative therapies. The company’s presentations at the summit will provide valuable insights into their ongoing trials and future directions in genetic medicine.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
